FR3073737B1 - La methode de traitement de la rhinosinusite - Google Patents

La methode de traitement de la rhinosinusite Download PDF

Info

Publication number
FR3073737B1
FR3073737B1 FR1771251A FR1771251A FR3073737B1 FR 3073737 B1 FR3073737 B1 FR 3073737B1 FR 1771251 A FR1771251 A FR 1771251A FR 1771251 A FR1771251 A FR 1771251A FR 3073737 B1 FR3073737 B1 FR 3073737B1
Authority
FR
France
Prior art keywords
compositions
rhinosinusitis
treatment method
quercetin
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1771251A
Other languages
English (en)
Other versions
FR3073737A1 (fr
Inventor
Ainura Chodoeva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphabio Therapeutics Fr
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1771251A priority Critical patent/FR3073737B1/fr
Application filed by Individual filed Critical Individual
Priority to EP18814794.6A priority patent/EP3713555A1/fr
Priority to CA3083179A priority patent/CA3083179A1/fr
Priority to US16/766,404 priority patent/US11351145B2/en
Priority to EA202090998A priority patent/EA202090998A1/ru
Priority to JP2020528007A priority patent/JP2021504325A/ja
Priority to CN201880087196.9A priority patent/CN111615384A/zh
Priority to PCT/EP2018/082241 priority patent/WO2019101867A1/fr
Publication of FR3073737A1 publication Critical patent/FR3073737A1/fr
Application granted granted Critical
Publication of FR3073737B1 publication Critical patent/FR3073737B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pour la prévention et le traitement des rhino sinusite s aiguë et chronique comprenant du sel; et des agents actifs du groupe polyphénolique choisis parmi les composés: quercétine, quercétine-4'-glucoside, 2-(3,4-dihydroxybenzoyl)-2,4,6-trihydroxy-3(2H)- benzofuranone, acide protocatéchique; La présente invention se rapporte également aux méthodes de préparation de ces compositions et à la méthode de traitement des rhino sinusite s aiguë et chronique avec ces compositions.
FR1771251A 2017-11-23 2017-11-23 La methode de traitement de la rhinosinusite Expired - Fee Related FR3073737B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR1771251A FR3073737B1 (fr) 2017-11-23 2017-11-23 La methode de traitement de la rhinosinusite
CA3083179A CA3083179A1 (fr) 2017-11-23 2018-11-22 Composition a base de quercetine pour le traitement de la rhinosinusite
US16/766,404 US11351145B2 (en) 2017-11-23 2018-11-22 Quercetin-based composition for treating rhinosinusitis
EA202090998A EA202090998A1 (ru) 2017-11-23 2018-11-22 Композиция на основе кверцетина для лечения риносинусита
EP18814794.6A EP3713555A1 (fr) 2017-11-23 2018-11-22 Composition à base de quercétine pour le traitement de la rhinosinusite
JP2020528007A JP2021504325A (ja) 2017-11-23 2018-11-22 鼻副鼻腔炎を治療するためのケルセチンベースの組成物
CN201880087196.9A CN111615384A (zh) 2017-11-23 2018-11-22 鼻窦炎的治疗方法
PCT/EP2018/082241 WO2019101867A1 (fr) 2017-11-23 2018-11-22 Composition à base de quercétine pour le traitement de la rhinosinusite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1771251 2017-11-23
FR1771251A FR3073737B1 (fr) 2017-11-23 2017-11-23 La methode de traitement de la rhinosinusite

Publications (2)

Publication Number Publication Date
FR3073737A1 FR3073737A1 (fr) 2019-05-24
FR3073737B1 true FR3073737B1 (fr) 2020-10-09

Family

ID=61750386

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1771251A Expired - Fee Related FR3073737B1 (fr) 2017-11-23 2017-11-23 La methode de traitement de la rhinosinusite

Country Status (8)

Country Link
US (1) US11351145B2 (fr)
EP (1) EP3713555A1 (fr)
JP (1) JP2021504325A (fr)
CN (1) CN111615384A (fr)
CA (1) CA3083179A1 (fr)
EA (1) EA202090998A1 (fr)
FR (1) FR3073737B1 (fr)
WO (1) WO2019101867A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11156623B2 (en) * 2018-12-20 2021-10-26 Public Joint Stock Company “Scientific Industrial Centre Borshchahivskiy Chemical-Pharmaceutical Plant” Methods of monitoring safety of quercetin compositions
KR20250051353A (ko) * 2023-10-10 2025-04-17 김천균 비염의 치료와 예방용 조성물 및 그 제조방법
CN120028107B (zh) * 2025-04-18 2025-08-08 长春赛默瑞特科技有限公司 一种有色冰冻包埋剂及其制备方法和冰冻包埋剂试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977184A (en) * 1995-09-15 1999-11-02 Thorne Research, Inc. Quercetin chalcone and methods related thereto
CH694219A5 (fr) * 2000-02-10 2004-09-30 Bobst Sa Procédé de mise en repérage automatique d'impressions dans une machine rotative et dispositif pour la mise en oeuvre du procédé.
CN102178675A (zh) * 2011-03-29 2011-09-14 深圳市药品检验所 槲皮素及其组合物在制备抗缺氧药物中的应用
CA2799881A1 (fr) 2011-12-20 2013-06-20 Water Pik, Inc. Solution de nettoyage nasal
CA2898040A1 (fr) * 2013-01-14 2014-07-17 Ent Associates Of Los Alamos, Llc Rincage nasal au miel
US20150231112A1 (en) * 2014-02-14 2015-08-20 Brian Stanislaws Paul Nasal and sinus wash compositions and methods
US10441621B2 (en) * 2015-09-23 2019-10-15 Reoxcyn, Llc Flavonoid compositions and methods of use

Also Published As

Publication number Publication date
US11351145B2 (en) 2022-06-07
CA3083179A1 (fr) 2019-05-31
EA202090998A1 (ru) 2020-09-10
JP2021504325A (ja) 2021-02-15
EP3713555A1 (fr) 2020-09-30
WO2019101867A1 (fr) 2019-05-31
CN111615384A (zh) 2020-09-01
FR3073737A1 (fr) 2019-05-24
US20210000787A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MA51530B1 (fr) Composés cycliques fondus
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA51673B1 (fr) Composés pour le traitement des troubles dépendants de kinases
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA40378A (fr) Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
MA40240B1 (fr) Composés hétéroaryle d'inhibition de la kinase
MA51627B1 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
MA41338B1 (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA38483A1 (fr) Inhibiteurs de l'ido
EA201691514A1 (ru) Соединения
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA54386B1 (fr) Modulateurs de trex1
EA200971050A1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
FR3073737B1 (fr) La methode de traitement de la rhinosinusite

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20190524

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: APHABIO THERAPEUTICS, FR

Effective date: 20200408

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

ST Notification of lapse

Effective date: 20230705